Literature DB >> 14689580

Emerging views of integrin signaling: implications for prostate cancer.

Jill K Slack-Davis1, J Thomas Parsons.   

Abstract

Integrins are heterodimeric transmembrane cellular receptors that link the cell to its underlying substratum. Alterations in integrin expression and signaling have been implicated in many aspects of tumorigenesis and metastasis including cell survival, migration, and invasion. In prostate cancer, the progression from normal to metastatic cells is accompanied by changes in the repertoire of integrins expressed and up-regulation of key adhesion-dependent signaling pathways. Recent work from several laboratories indicates the emergence of new mechanisms for the regulation of growth and migratory pathways by integrin engagement. These pathways are likely to provide novel sites of therapeutic intervention for the treatment of prostate cancer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14689580     DOI: 10.1002/jcb.10665

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  21 in total

1.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

2.  Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5.

Authors:  Thomas C Sroka; Michael E Pennington; Anne E Cress
Journal:  Carcinogenesis       Date:  2006-03-14       Impact factor: 4.944

3.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Authors:  Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

4.  Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer.

Authors:  Chiun-Wei Huang; Zibo Li; Hancheng Cai; Kai Chen; Tony Shahinian; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

5.  Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.

Authors:  Apollo D Kacsinta; Cynthia S Rubenstein; Isis C Sroka; Sangita Pawar; Jaime M Gard; Raymond B Nagle; Anne E Cress
Journal:  Biochem Biophys Res Commun       Date:  2014-10-22       Impact factor: 3.575

Review 6.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

7.  Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.

Authors:  Joseph L Sottnik; Stephanie Daignault-Newton; Xiaotun Zhang; Colm Morrissey; Maha H Hussain; Evan T Keller; Christopher L Hall
Journal:  Clin Exp Metastasis       Date:  2012-12-15       Impact factor: 5.150

8.  Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer.

Authors:  Edward W Howard; Steve C L Leung; H F Yuen; Chee Wai Chua; Davy T Lee; K W Chan; Xianghong Wang; Yong Chuan Wong
Journal:  Clin Exp Metastasis       Date:  2008-03-14       Impact factor: 5.150

9.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

Authors:  Christopher L Hall; Cara W Dubyk; Tracy A Riesenberger; Daniel Shein; Evan T Keller; Kenneth L van Golen
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.

Authors:  Shibu Thomas; Maurizio Chiriva-Internati; Girish V Shah
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.